Ciobanu George Adrian, Camen Adrian, Ionescu Mihaela, Vlad Daniel, Munteanu Cristina Maria, Gheorghiță Mircea Ionuț, Lungulescu Cristian Virgil, Staicu Ionela Elisabeta, Sin Elena Claudia, Chivu Luminița, Mercuț Răzvan, Popescu Sanda Mihaela
Department of Oral Rehabilitation, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
Department of Oral and Maxillofacial Surgery, Dental Medicine Faculty, "Ovidius" University of Constanța, 900470 Constanța, Romania.
J Clin Med. 2023 May 29;12(11):3747. doi: 10.3390/jcm12113747.
MRONJ (Medication-Related Osteonecrosis of the Jaw) is a condition observed in a subset of cancer patients who have undergone treatment with zoledronic acid in order to either prevent or treat bone metastases. The primary aim of this research was to establish the importance of risk factors in the development of medication-related osteonecrosis of the jaw in cancer patients receiving zoledronic acid therapy for bone metastases. The present study is an observational retrospective investigation conducted at two university centers, namely, Craiova and Constanța, and included cancer patients treated with zoledronic acid. The medical records of the patients were obtained over a four-year timeframe spanning from June 2018 to June 2022. The data analysis was carried out between January 2021 and October 2022. Patients were treated for cancer, bone metastases, and MRONJ according to the international guidelines. The research investigated a cohort of 174 cancer patients (109 females and 65 males) aged between 22 and 84 years (with a mean age 64.65 ± 10.72 years) seeking treatment at oncology clinics situated in Craiova and Constanța. The study conducted a binomial logistic regression to analyze ten predictor variables, namely, gender, age, smoking status, treatment duration, chemotherapy, radiotherapy, endocrine therapy, presence of diabetes mellitus (DM), obesity, and hypertension (HT). The results of the analysis revealed that only five of the ten predictor variables were statistically significant for MRONJ occurrence: duration of treatment ( < 0.005), chemotherapy ( = 0.007), and hypertension ( = 0.002) as risk factors, and endocrine therapy ( = 0.001) and obesity ( = 0.024) as protective factors.
颌骨药物相关性骨坏死（MRONJ）是在部分癌症患者中观察到的一种病症，这些患者接受了唑来膦酸治疗以预防或治疗骨转移。本研究的主要目的是确定风险因素在接受唑来膦酸治疗骨转移的癌症患者发生颌骨药物相关性骨坏死中的重要性。本研究是在两个大学中心，即克拉约瓦和康斯坦察进行的一项观察性回顾性调查，纳入了接受唑来膦酸治疗的癌症患者。患者的医疗记录是在2018年6月至2022年6月的四年时间内获取的。数据分析在2021年1月至2022年10月期间进行。患者按照国际指南接受癌症、骨转移和MRONJ的治疗。该研究调查了一组174名年龄在22岁至84岁之间（平均年龄64.65±10.72岁）的癌症患者（109名女性和65名男性），他们在克拉约瓦和康斯坦察的肿瘤诊所寻求治疗。该研究进行了二项逻辑回归分析十个预测变量，即性别、年龄、吸烟状况、治疗持续时间、化疗、放疗、内分泌治疗、糖尿病（DM）的存在、肥胖和高血压（HT）。分析结果显示，十个预测变量中只有五个对MRONJ的发生具有统计学意义：治疗持续时间（<0.005）、化疗（=0.007）和高血压（=0.002）作为风险因素，内分泌治疗（=0.001）和肥胖（=0.024）作为保护因素。
